JunekoElaineGrilley-OlsonMD(She/Her)

Oncology • Durham, NC

Sarcoma

Associate Professor, Medicine, Duke School of Medicine

Join to view full profile

Dr. Grilley-Olson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grilley-Olson's full profile

Already have an account?

Office
Duke Cancer Center
20 Duke Medicine Cir
Durham, NC 27710
Phone+1 919-613-5550

Summary

Dr. Juneko Grilley-Olson is an oncologist in Durham, NC and is affiliated with Duke University. She received her medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 14 years. She specializes in sarcoma, and developmental therapeutics.

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
Hennepin HealthcareResidency, Internal Medicine, 2003 - 2006
University of Wisconsin School of Medicine & Public HealthClass of 2003

Certifications & Licensure

NC State Medical License 2006 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Start of enrollment: 2013 Oct 01
Terminated
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN Start of enrollment: 2014 Jun 16
Completed
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma Start of enrollment: 2020 Nov 04
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.
Laura H Rosenberger, Richard F Riedel, Emilia J Diego, Amanda L Nash, Juneko E Grilley-Olson
The Oncologist. 2024-12-06
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
Rani Bansal, Tolulope Adeyelu, Andrew Elliott, Antoinette R Tan, Jennifer R Ribeiro
JCO Precision Oncology. 2024-12-01
3 citations
Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020.
Michael J Wagner, Vinod Ravi, Stephanie K Schaub, Ed Y Kim, Jeremy Sharib
JAMA Network Open. 2024-04-01

Lectures

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Largest-Ever Precision Medicine Oncology Trial Ready for LaunchJune 1st, 2015

Professional Memberships

American Society of Clinical Oncology - ASCO
Member